NASD · Healthcare · Biotechnology · Canada
Milestone Pharmaceuticals Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Milestone Pharmaceuticals is a biopharmaceutical company that develops and markets medicines for heart conditions. Its approved product CARDAMYST (etripamil) is a nasal spray available in the United States that patients can self-administer to treat acute episodes of PSVT. The company also develops etripamil for treating atrial fibrillation with rapid ventricular rate.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Milestone Pharmaceuticals Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: it has no growth history of its own to project.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on MIST yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history. We do not have it. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-30 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history. We do not have it. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.